Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ADPT
Adaptive Biotechnologies Corporation Common Stock
stock NASDAQ

At Close
Jul 28, 2026 3:59:59 PM EDT
22.52USD-0.089%(-0.02)1,678,788
19.15Bid   22.65Ask   3.50Spread
Pre-market
Jul 27, 2026 9:28:30 AM EDT
22.69USD+1.886%(+0.42)0
After-hours
Jul 27, 2026 4:20:30 PM EDT
21.45USD-4.836%(-1.09)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
04:05PM EST  Adaptive Biotechnologies to Report Fourth Quarter and Full Year   GlobeNewswire Inc
Jan 10, 2022
08:32AM EST  Adaptive Biotech Sees FY21 Sales $153M-$154M vs $153.1M Estimate   Benzinga
08:30AM EST  Adaptive Biotechnologies Announces Preliminary, Unaudited 2021   GlobeNewswire Inc
Jan 4, 2022
04:05PM EST  Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT),a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.   GlobeNewswire Inc
Dec 13, 2021
04:06PM EST  Adaptive Biotechnologies Announces New Data Demonstrating The Benefit Of Serial MRD Testing With The clonoSEQ Assay In Patients With Blood Cancers At The 63rd ASH Annual Meeting   Benzinga
04:05PM EST  -- Analysis of the MASTER trial (Abstract 481) showed clonoSEQs ability to measure deep and durable responses and permit treatment discontinuation in multiple myeloma patients -- Data in more than 30 abstracts supports clonoSEQ as a standard of care in blood cancers, delivering relevant and timely clinical insights to physicians, patients and investigators   GlobeNewswire Inc
Dec 2, 2021
08:16AM EST  Adaptive Biotechnologies, Collaborators To Present Over 30 Abstracts On Utility Of clonoSEQ In MRD Testing In Blood Cancer Patients At 63rd ASH Annual Meeting On Dec. 11-14   Benzinga
08:00AM EST  Adaptive Biotechnologies and Collaborators to Present More than 30   GlobeNewswire Inc
Nov 12, 2021
07:47AM EST  The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares   Benzinga
Nov 11, 2021
05:56PM EST  Adaptive Biotechnologies Receives Updated Medicare Coverage For Its Minimal Residual Disease (MRD) Assay, clonoSEQ For Blood Cancer Patients   Benzinga
05:53PM EST  -- Local coverage determination (LCD) confirms access to the only FDA-cleared in vitro diagnostic to detect and monitor minimal residual disease (MRD) from bone marrow and blood sample types in certain blood cancers -- LCD supports the expansion of coverage for additional clonoSEQ indications, providing a clear pathway for Non-Hodgkins Lymphoma (NHL) and other lymphoid cancers   GlobeNewswire Inc
Nov 3, 2021
05:42PM EDT  Adaptive Biotechnologies Reiterates FY21 Sales Guidance Of $148M-$155M vs $150.16M Est.   Benzinga
05:41PM EDT  Adaptive Biotechnologies Q3 EPS $(0.40) Beats $(0.42) Estimate, Sales $39.50M Beat $36.64M Estimate   Benzinga
09:19AM EDT  The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering   Benzinga
09:10AM EDT  Earnings Scheduled For November 3, 2021   Benzinga
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 22, 2021
07:36AM EDT  The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs   Benzinga
Oct 6, 2021
04:05PM EDT  Adaptive Biotechnologies to Report Third Quarter Financial Results   GlobeNewswire Inc
Oct 2, 2021
01:15PM EDT  Real-world data show T-Detect COVID can detect prior SARS-CoV-2 infection nearly 12 months after initial diagnosis in some patients   GlobeNewswire Inc
Sep 30, 2021
07:33AM EDT  Adaptive Biotechnologies Launches Enhanced clonoSEQ Assay Reports For Patients With Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status   Benzinga
07:30AM EDT  Adaptive Biotechnologies Launches Enhanced clonoSEQ   GlobeNewswire Inc
Sep 23, 2021
12:49PM EDT  Adaptive Biotechnologies Sponsored Study Titled 'ImmuneSense COVID-19 Variant Study' Posted To ClinicalTrials.gov; Study Is Not Yet Recruiting   Benzinga
Sep 21, 2021
04:05PM EDT  Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the opening of its new corporate headquarters and laboratory facility located in the heart of South Lake Union Seattles life sciences hub.   GlobeNewswire Inc
Sep 16, 2021
08:15AM EDT  Adaptive Biotechnologies To Present New SARS-CoV-2 Data From Its Immune Medicine Platform During IDWeek 2021 Sept. 29 To Oct. 3   Benzinga
08:04AM EDT  Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its   GlobeNewswire Inc
Sep 7, 2021
05:15PM EDT  Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.   GlobeNewswire Inc
Aug 20, 2021
02:36PM EDT  Return on Capital Employed Insights for Adaptive Biotechnologies   Benzinga
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 10, 2021
02:20PM EDT  Curebase, Adaptive Biotechnologies Announce Collaboration To Expand Clinical Study Access   Benzinga
02:12PM EDT  Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical   PR Newswire
Aug 6, 2021
08:15AM EDT  Goldman Sachs Maintains Neutral on Adaptive Biotechnologies, Lowers Price Target to $52   Benzinga
Aug 5, 2021
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
Aug 4, 2021
05:00PM EDT  Adaptive Biotechnologies Revises FY21 Sales Guidance From $145M-$155M To $148M-$155M vs $150.16M Est.   Benzinga
04:59PM EDT  Adaptive Biotechnologies Q2 EPS $(0.35) Beats $(0.42) Estimate, Sales $38.50M Beat $31.26M Estimate   Benzinga
04:05PM EDT  Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2021.   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 4, 2021   Benzinga
Jul 12, 2021
04:07PM EDT  Adaptive Biotechnologies to Report Second Quarter Financial   GlobeNewswire Inc
Jun 9, 2021
07:18AM EDT  Adaptive Biotechnologies Corporation Highlights Publication Of Study Using immunoSEQ T-MAP COVID   Benzinga
07:15AM EDT  New Study Published in Nature Provides Further Evidence that   GlobeNewswire Inc
Jun 3, 2021
07:40AM EDT  Adaptive Biotechnologies Highlights Inclusion In Abstracts At ASCO And EHA 2021   Benzinga
07:30AM EDT  Adaptive Biotechnologies Included in More than 20 Abstracts at   GlobeNewswire Inc
May 20, 2021
04:05PM EDT  Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the following investor conferences.   GlobeNewswire Inc
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:42AM EDT  Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $55   Benzinga
May 5, 2021
04:41PM EDT  Adaptive Biotechnologies Q1 EPS $(0.29) Beats $(0.41) Estimate, Adj. EBITDA Loss $30.1M, Sales $38.40M Beat $27.75M Estimate; Sees FY21 Sales $145M-$155M vs $149.9M Est.   Benzinga
04:05PM EDT  Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March31, 2021.   GlobeNewswire Inc
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
04:16AM EDT  Earnings Scheduled For May 5, 2021   Benzinga
May 4, 2021
10:27AM EDT  Earnings Outlook for Adaptive Biotechnologies   Benzinga
Apr 27, 2021
04:05PM EDT  Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.   GlobeNewswire Inc
Apr 12, 2021
04:05PM EDT  Adaptive Biotechnologies to Report First Quarter Financial Results   GlobeNewswire Inc
Mar 30, 2021
12:04AM EDT  Apple, Netflix, Peloton, Square, Roku, DraftKings - What Cathie Wood's Ark Bought And Sold On Monday   Benzinga
Mar 17, 2021
04:05PM EDT  Adaptive Biotechnologies Strengthens Expertise and Diversity of   GlobeNewswire Inc
Mar 8, 2021
10:02AM EST  Adaptive Biotechnologies shares were trading higher after the company's COVID-19 test received FDA emergency use authorization.   Benzinga
09:12AM EST  Looking Into Adaptive Biotechnologies's Return On Capital Employed   Benzinga
08:47AM EST  The U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection.   RTTNews
05:34AM EST  Adaptive Biotechnologies Secures FDA EUA For COVID-19 T-Cell Response Test   Benzinga
Mar 5, 2021
06:45PM EST  First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19   GlobeNewswire Inc
Mar 3, 2021
10:02AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2021   Benzinga
08:59AM EST  Goldman Sachs Downgrades Adaptive Biotechnologies to Neutral, Lowers Price Target to $63   Benzinga
Mar 2, 2021
06:54PM EST  ARK Invest's Cathie Wood To Appear On Benzinga's 'The Raz Report' Wednesday, Mar. 3, 2021 At 2 p.m. EST; Register Early For A Chance To Win To Ask Cathie A Question Live On Air   Benzinga
Feb 26, 2021
08:28AM EST  Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $60   Benzinga
Feb 24, 2021
05:32PM EST  Adaptive Biotechnologies: Q4 Earnings Insights   Benzinga
05:31PM EST  Adaptive Biotechnologies Corp. (ADPT) Wednesday reported fourth-quarter loss of $44.6 million or $0.33 per share, wider than last year's loss of $20.6 million or $0.17 per share last year.   RTTNews
04:26PM EST  Adaptive Biotech Reports Expansion Of Collaboration With Labcorp To Increase Access To Research, Clinical Diagnostic Portfolio   Benzinga
04:24PM EST  Adaptive Biotechnologies Q4 Loss/share $0.33 Vs. Loss $0.17 Year Ago   RTTNews
04:05PM EST  Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December31, 2020.   GlobeNewswire Inc
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
03:35AM EST  Earnings Scheduled For February 24, 2021   Benzinga
Feb 23, 2021
12:43PM EST  Adaptive Bio Launches T-Cell Based COVID-19 Tests   Benzinga
09:15AM EST  Adaptive Biotechnologies Expands Collaboration with Labcorp to   GlobeNewswire Inc
07:31AM EST  Adaptive Biotechnologies Highlights Launch Of T-Detect COVID T-Cell Based Test For Patients To Confirm Recent Or Prior COVID-19 Infection   Benzinga
07:30AM EST  T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA)   GlobeNewswire Inc
Feb 2, 2021
04:05PM EST  Adaptive Biotechnologies to Report Fourth Quarter and Full Year   GlobeNewswire Inc
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 19, 2021
05:23AM EST  Adaptive Biotechnologies Issued U.S. Patent 10,894,977 'Compositions and methods for measuring and calibrating amplification bias in multiplexed PCR reactions'   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 11, 2021
04:01PM EST  Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics   Benzinga
04:01PM EST  Multi-year, pan-portfolio deal extends Adaptives proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology   GlobeNewswire Inc
Dec 30, 2020
04:30PM EST  Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT),a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference.   GlobeNewswire Inc
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 22, 2020
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 11, 2020
08:11AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street   Benzinga
Dec 6, 2020
10:00AM EST  Adaptive Biotechnologies Announces New Clinical Data Demonstrating   GlobeNewswire Inc
Nov 23, 2020
08:00AM EST  -- Studies reinforce clonoSEQ as standard of care in minimal residual disease (MRD) across eight disease states -- Real-world evidence shows treatment decisions based on precise MRD measurement directly correlate with improved patient outcomes and cost savings   GlobeNewswire Inc
Nov 13, 2020
08:04AM EST  Adaptive Biotechnologies Announces Prelim. Data Comparing T-Cell Testing And Antibody Testing In Identifying Past SARS-CoV-2 Infections; Says Findings Support Launch Of T-Detect   Benzinga
08:04AM EST  Adaptive Biotechnologies Reports Its T-Detect Assay For Past SARS-CoV-2 Infection In Development Identified 97% (68/70) Of Past PCR-Confirmed SARS-CoV-2 Infections   Benzinga
08:00AM EST  Findings support upcoming launch of T-Detect COVID, first T-cell test for novel coronavirus Data support mounting evidence that measuring T-cells is necessary tofully characterize immune responsesto SARS-CoV-2 across the population Additional supporting datato be published soon   GlobeNewswire Inc
Nov 11, 2020
07:42AM EST  Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $46   Benzinga
Nov 10, 2020
05:22PM EST  Recap: Adaptive Biotechnologies Q3 Earnings   Benzinga
04:17PM EST  Adaptive Biotechnologies Q3 Loss/Shr $0.27 Vs Loss $0.11 Last Year   RTTNews
04:15PM EST  Adaptive Biotechnologies Q3 EPS $(0.27) Beats $(0.28) Estimate, Sales $26.30M Beat $23.58M Estimate   Benzinga
04:13PM EST  Adaptive Biotechnologies Corporation (Nasdaq: ADPT),a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a collaboration with GlaxoSmithKline plc (GSK) to use its clonoSEQ Assay to assess minimal residual disease (MRD) in GSKs portfolio of hematology products.   GlobeNewswire Inc
04:10PM EST  Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2020.   GlobeNewswire Inc
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Oct 13, 2020
04:05PM EDT  Adaptive Biotechnologies to Report Third Quarter Financial Results   GlobeNewswire Inc
Sep 9, 2020
07:35AM EDT  Morgan Stanley Initiates Coverage On Adaptive Biotechnologies with Equal-Weight Rating, Announces Price Target of $42   Benzinga
Sep 1, 2020
04:03PM EDT  Adaptive Biotechnologies Corporation (Nasdaq: ADPT),a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.   GlobeNewswire Inc
Aug 11, 2020
11:00AM EDT  Adaptive Biotechnologies shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.   Benzinga
Aug 10, 2020
04:59PM EDT  Adaptive Biotechnologies Corp. (ADPT) Monday reported second-quarter net loss of $33.5 million or $0.26 per share, compared to $16.4 million or $1.23 per share last year.   RTTNews
04:15PM EDT  Adaptive Biotechnologies Q2 Loss/Shr $0.26 Vs Loss $1.23 Last Year   RTTNews
04:11PM EDT  Adaptive Biotechnologies Q2 EPS $(0.26) Beats $(0.28) Estimate, Sales $21.00M Beat $18.80M Estimate   Benzinga
04:05PM EDT  Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2020.   GlobeNewswire Inc
08:05AM EDT  Adaptive Biotechnologies Corporation (Nasdaq: ADPT),a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit.   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 6, 2020
09:31AM EDT  Adaptive Biotechnologies Receives Expanded FDA Clearance For The ClonoSEQ Assay To Assess Minimal Residual Disease In Patients With Chronic Lymphocytic Leukemia   Benzinga
Aug 4, 2020
09:50AM EDT  Adaptive Biotechnologies Launches ImmunoSEQ T-MAP COVID, T Cell Monitoring Tool For SARS-CoV-2   RTTNews
09:46AM EDT  Adaptive Biotechnologies Launches ImmunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool For SARS-CoV-2   Benzinga
09:31AM EDT  Tailored for vaccine developers to accurately and reproducibly measure and track COVID-19 specific T-cell response in clinical trials   GlobeNewswire Inc
Jul 28, 2020
08:43PM EDT  Adaptive Launches National Clinical Trial To Develop Novel T-Cell Based Diagnostic For Lyme Disease   RTTNews
06:05PM EDT  Adaptive Biotech Highlights Launch Of National Clinical Trial To Develop Novel T-Cell Based Diagnostic For Lyme Disease   Benzinga
Jul 17, 2020
05:08AM EDT  64 Biggest Movers From Yesterday   Benzinga
Jul 16, 2020
05:24PM EDT  Adaptive Biotechnologies Sees Q2 EPS $(0.25)   Benzinga
05:23PM EDT  Adaptive Biotechnologies Sees Total Rev For Quarter Ended June 30 To Range From $20M-$20.5M; Expects Operating And Net Loss To Increase YoY   Benzinga
06:23AM EDT  Adaptive Biotechnologies Prices 8M Share Public Offering of Common Stock @$40/Share   Benzinga
Jul 15, 2020
07:47PM EDT  Adaptive Biotechnologies Announces Pricing of Public Offering of   GlobeNewswire Inc
Jul 14, 2020
04:47PM EDT  Adaptive Biotech Reports 8M Share Offering   Benzinga
04:45PM EDT  Adaptive Biotechnologies Announces Proposed Public Offering of   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC